OCREVUS ZUNOVO
Clinical safety rating
cautionComprehensive clinical and safety monograph for OCREVUS ZUNOVO (OCREVUS ZUNOVO).
Comprehensive clinical and safety monograph for OCREVUS ZUNOVO (OCREVUS ZUNOVO).
FDA: Treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.FDA: Treatment of primary progressive multiple sclerosis (PPMS).
OCREVUS ZUNOVO is a recombinant humanized monoclonal antibody that targets CD20-positive B cells. It binds to the CD20 antigen on the surface of pre-B and mature B lymphocytes, leading to antibody-dependent cellular cytotoxicity and complement-mediated lysis, resulting in B-cell depletion.
| Metabolism | Ocrevus Zunovo is a monoclonal antibody that is degraded into small peptides and amino acids via general protein catabolism. No specific metabolic pathways or enzymes are involved. |
| Excretion | Ocrelizumab is metabolized via catabolism into small peptides and amino acids; no specific excretion studies have been conducted. Based on its monoclonal antibody structure, it is not excreted renally or biliary unchanged. Elimination is primarily through intracellular catabolism, with no urinary or fecal excretion of intact drug. |
| Half-life | Terminal elimination half-life is approximately 26 days (range 20–30 days). This long half-life supports every-6-month dosing. Multiple doses lead to steady-state by 24 weeks. |
| Protein binding | Ocrelizumab is a monoclonal antibody; typical IgG binding to FcRn is pH-dependent, but standard protein binding experiments are not performed. It does not primarily bind to plasma proteins like albumin; thus, reported free fraction is >95% unbound, with minimal nonspecific binding. |
| Volume of Distribution | Volume of distribution is approximately 2.7 L (0.04 L/kg for a 70 kg patient), indicating limited extravascular distribution, consistent with a large monoclonal antibody primarily confined to plasma and interstitial space. |
| Bioavailability | Subcutaneous: Bioavailability is approximately 50–60% (absolute bioavailability not determined; relative to IV, AUC is 65%). Not available for other routes. |
| Onset of Action | Subcutaneous injection: Clinical onset occurs within 12 weeks, as measured by reduction in gadolinium-enhancing lesions in relapsing multiple sclerosis. For intravenous administration (historical), time to B-cell depletion is about 2 weeks. |
| Duration of Action | Dosing every 6 months maintains therapeutic effect. B-cell recovery begins around 24 weeks after a dose but may take up to 1 year to return to normal levels. Clinical effect on relapses persists through the dosing interval. |
| Molecular Weight | 145000 |
Initial dose: 300 mg intravenous infusion over 4 hours followed 2 weeks later by a second 300 mg intravenous infusion over 4 hours. Subsequent doses: 600 mg intravenous infusion over 3.5 hours every 6 months.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (GFR <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild hepatic impairment (Child-Pugh A). Not studied in moderate or severe hepatic impairment (Child-Pugh B or C). |
| Pediatric use | Safety and efficacy not established in pediatric patients. No approved dosing. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Clinical studies included patients up to age 65 with no dose modifications. |
| 1st trimester | Ocrelizumab is a humanized monoclonal antibody targeting CD20. IgG antibodies cross the placenta in significant amounts only after the first trimester. For T1, placental transfer is minimal, but available data are limited. The drug should be used only if clearly needed and benefit outweighs potential risk. |
| 2nd trimester | During T2, placental transfer of IgG increases. Ocrelizumab may cause fetal B-cell depletion and lymphopenia. Use only if potential benefit justifies potential risk to the fetus. |
| 3rd trimester | In T3, substantial placental transfer occurs. Newborns may have peripheral B-cell depletion, lymphopenia, and increased risk of infection. Vaccination with live vaccines should be delayed until B-cell counts recover. Use only if clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for OCREVUS ZUNOVO (OCREVUS ZUNOVO).
| Placental transfer | Ocrelizumab is an IgG1 monoclonal antibody and actively transported across the placenta via FcRn receptors, with increasing transfer as pregnancy progresses. Highest transfer occurs during the third trimester. Cord blood levels can reach 100% of maternal levels. |
| Breastfeeding | Ocrelizumab is present in breast milk in low concentrations. It is a large protein likely degraded in the infant's gastrointestinal tract, leading to minimal oral bioavailability. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need for the drug and any potential adverse effects on the breastfed infant. |
| Lactation Rating | L3: Moderately Safe |
| Teratogenic Risk | Ocrelizumab (OCREVUS ZUNOVO) is a humanized anti-CD20 monoclonal antibody that crosses the placenta. In first trimester, B-cell depletion may occur; second and third trimester exposure is associated with fetal B-cell lymphocytopenia and potential increased infection risk. Animal studies show no direct teratogenicity, but human data are limited. Avoid during pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor complete blood count with differential, and immunoglobulin levels at baseline and periodically. During pregnancy, assess fetal B-cell counts if exposure occurs in second/third trimester. Evaluate infant for infections, live vaccine response (avoid until B-cell recovery), and ensure pediatrician aware of exposure history. |
| Fertility Effects | Ocrelizumab does not directly impair fertility; however, disease activity (multiple sclerosis) may affect reproductive health. No human data on ovarian reserve. B-cell depletion may rarely affect conception indirectly via infection risk. Advise comprehensive reproductive counseling. |
■ FDA Black Box Warning
WARNING: INFUSION-RELATED REACTIONS, HYPERSENSITIVITY, AND INCREASED RISK OF INFECTIONS. Infusion-related reactions can occur during or after infusion, including anaphylaxis, acute respiratory distress syndrome, urticaria, and hypotension. Hypersensitivity reactions, including anaphylaxis, have been reported. Ocrevus Zunovo increases the risk of upper respiratory tract infections, lower respiratory tract infections, and herpes infections. Patients should be monitored during infusion and for at least one hour post-infusion.
| Serious Effects |
Active hepatitis B infectionLife-threatening infusion reaction to ocrelizumabKnown severe hypersensitivity to ocrelizumab or any of its excipients
| Precautions | Infusion reactions: premedicate with corticosteroids and antihistamines; monitor during infusion and for at least 1 hour after., Infections: increased risk, especially upper and lower respiratory tract infections and herpes infections; delay administration in patients with active infection., Hepatitis B virus reactivation: screen all patients for HBV; do not start in patients with active hepatitis., Progressive multifocal leukoencephalopathy (PML): withhold if PML suspected; discontinue if confirmed., Vaccination: administer all required vaccines at least 4 weeks prior to starting therapy; live vaccines not recommended during treatment., Immunoglobulin levels: monitor; consider discontinuation if low., Fetal harm: may cause fetal harm; advise effective contraception during and for 3 months after last infusion. |
| Food/Dietary | No known food interactions. Ocrevus Zunovo may be administered without regard to meals. |
| Clinical Pearls | Ocrevus Zunovo (ocrelizumab/hyaluronidase) is a subcutaneous formulation of ocrelizumab with recombinant human hyaluronidase to facilitate absorption. Administer subcutaneously in the abdomen over approximately 10 minutes. Premedicate with methylprednisolone (100 mg IV or equivalent oral) and an antihistamine (e.g., diphenhydramine 50 mg) approximately 30 minutes prior to each injection to reduce infusion reactions. Monitor for injection-site reactions, including erythema, pain, and swelling. Live-attenuated vaccines are contraindicated during treatment and until B-cell repletion. Do not administer if active infection is present. |
| Patient Advice | Ocrevus Zunovo is given as a subcutaneous injection every 6 months after the initial two doses separated by 2 weeks. · You will receive premedication before each injection to reduce the risk of allergic reactions. · Common side effects include injection-site reactions, headache, and upper respiratory tract infections. · Avoid live vaccines (e.g., MMR, varicella, intranasal flu) during treatment and for at least 4 weeks before starting. · Contact your healthcare provider immediately if you develop symptoms of infection, such as fever, chills, or cough. |
Loading safety data…